| Title | Seizure relapse and development of drug resistance following long-term seizure remission. | | Author(s) | Schiller Y | | Institution | Epilepsy Service, Department of Neurology, Rambam Medical Center, 1 Efron St, Haifa 31096, Israel. y_schiller@yahoo.com | | Source | Arch Neurol 2009 Oct; 66(10):1233-9. | | MeSH | Adult
Anticonvulsants
Cohort Studies
Drug Resistance
Electroencephalography
Epilepsy
Female
Follow-Up Studies
Humans
Kaplan-Meiers Estimate
Long-Term Care
Male
Multivariate Analysis
Prognosis
Prospective Studies
Recurrence
Risk Factors
Seizures
Survival Analysis
| | Abstract | OBJECTIVE: To quantify and identify predictive risk factors for seizure relapse and development of drug resistance in patients who achieved long-term (>1 year) antiepileptic drug-induced seizure remission.
DESIGN: Prospective cohort study.
SETTING: Epilepsy Center, Rambam Medical Center. Patients Two hundred fifty-six consecutive patients who entered long-term (>1 year) antiepileptic drug-induced seizure remission were followed up prospectively for 2 years or more.
MAIN OUTCOME MEASURES: Seizure relapse and development of drug-resistant epilepsy.
RESULTS: Five years after entering seizure remission, 40.2% of patients experienced seizure relapse and 25.3% of patients developed drug-resistant epilepsy. The Kaplan-Meier curves could be fitted by monoexponential functions, with a maximal seizure relapse rate of 43.6%, maximal drug-resistance rate of 27.4%, and half-decay constant of 21.5 months for both curves. Treatment history served as a significant independent prognostic risk factor for both seizure relapse and development of drug resistance. The preremission seizure frequency and duration of epilepsy were also identified as significant prognostic risk factors in the univariant analysis but failed to reach statistical significance in the multivariate analysis.
CONCLUSION: Seizure relapse commonly occurs in patients following long-term seizure remission. Treatment history and duration of epilepsy are predictive risk factors for both seizure relapse and development of drug resistance. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19822778 |
|
